ONCSQ (OncoSec Medical) EV-to-EBIT: 0.00 (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is OncoSec Medical EV-to-EBIT?

OncoSec Medical ONCSQ -99.00% EV-to-EBIT is 0.00 as of Jul. 21, 2026.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, OncoSec Medical's Enterprise Value is $0.00 Mil. OncoSec Medical's EBIT for the trailing twelve months (TTM) ended in Jan. 2023 was $-32.67 Mil. Therefore, OncoSec Medical's EV-to-EBIT for today is 0.00.

The historical rank and industry rank for OncoSec Medical's EV-to-EBIT or its related term are showing as below:

ONCSQ's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 13.315
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. OncoSec Medical's Enterprise Value for the quarter that ended in Jan. 2023 was $6.32 Mil. OncoSec Medical's EBIT for the trailing twelve months (TTM) ended in Jan. 2023 was $-32.67 Mil. OncoSec Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2023 was -517.03%.

OncoSec Medical  (OTCPK:ONCSQ) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

OncoSec Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jan. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Jan. 2023 ) =EBIT / Enterprise Value (Q: Jan. 2023 )
=-32.667/6.3182
=-517.03 %

OncoSec Medical's Enterprise Value for the quarter that ended in Jan. 2023 was $6.32 Mil.
OncoSec Medical's EBIT for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical EV-to-EBIT Related Terms

OncoSec Medical EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for OncoSec Medical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

OncoSec Medical EV-to-EBIT Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.01 0.04 -1.95 -0.98 -0.59

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.41 -0.45 -0.59 -0.45 -0.19

ONCSQ vs NOVNQ, USRM, VRTX: EV-to-EBIT Comparison

For the Biotechnology subindustry, OncoSec Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoSec Medical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's EV-to-EBIT falls into.


OncoSec Medical EV-to-EBIT Calculation

OncoSec Medical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=0.000/-32.667
=0.00

OncoSec Medical's current Enterprise Value is $0.00 Mil.
OncoSec Medical's EBIT for the trailing twelve months (TTM) ended in Jan. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-32.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-EBIT →
What does a EV-to-EBIT of 0.00 mean?
OncoSec Medical (ONCSQ) has a EV-to-EBIT of 0.00 as of Jul. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OncoSec Medical and its competitors.
Is OncoSec Medical's EV-to-EBIT too high?
OncoSec Medical's current EV-to-EBIT is 0.00.
How does OncoSec Medical's EV-to-EBIT compare to NOVNQ and USRM?
OncoSec Medical's EV-to-EBIT of 0.00 can be compared against companies in the Biotechnology industry. The industry median EV-to-EBIT is 13.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 13.32, based on 372 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on OncoSec Medical and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 13.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. OncoSec Medical's current EV-to-EBIT is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoSec Medical stock overvalued right now?
OncoSec Medical (ONCSQ) has a current EV-to-EBIT of 0.00. The current EV-to-EBIT is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For OncoSec Medical (ONCSQ), the current EV-to-EBIT is 0.00 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

OncoSec Medical Business Description

Address 820 Bear Tavern Road, Ewing, NJ, USA, 08628-1021
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.